Enter inventor name

Eugen Falk

This inventor holds 31 USPTO granted patents and 1 published patent application and 9 EPO patents. Top assignees: Sanofi-A Ventis Deutschland Gmbh, Aventis Pharma Deutschland, Gmbh, Sanofi-Aventis. Active years: 2000-2015.

USPTO Granted Patents = 31 (Patent Applications = 1)

% Patents Active = 54.8

EPO Patents = 9 (Patent Applications = 3)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 256(Granted Patents)

Location History:

Franfurt, DE (2002)
Frankfurt-am-Main, DE (2000 - 2015)

Company Filing History:

13 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

patents

10 out of 330

Aventis Pharma Deutschland, Gmbh

Hoechst Aktiengesellschaft

Years Active: 2000-2015

Loading Chart...

Areas of Expertise:

Sulfonamides

Oxadiazolone

PPAR Ligands

Pharmaceutical Compositions

Cycloalkyl Derivatives

Arylcycloalkyl Derivatives

Hypolipidemic Agents

Thiadiazole Compounds

Acidic Heterocycles

Propanolamine Derivatives

Carboxamide Derivatives

Acylguanidines

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8946212 - Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals (2015-02-03),

2. 8329725 - Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals (2012-12-11),

3. 8173674 - Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals (2012-05-08),

4. 8048901 - 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals (2011-11-01),

5. 7956077 - 2-{-3,'2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes (2011-06-07),

6. 7910612 - 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for their therapeutic use (2011-03-22),

7. 7872034 - Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals (2011-01-18),

8. 7858647 - N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use (2010-12-28),

9. 7732471 - 6-oxazol-4-ylmetholmethoxy-alko-alkoxymethyl substituted benzoic acid derivatives forming peroxisome proliferator—activated receptor (PPAR) ligands, process for their preparation and methods of use thereof (2010-06-08),

10. 7601863 - Use of PPAR agonists for the treatment of congestive heart failure (2009-10-13),

11. 7598281 - Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes (2009-10-06),

12. 7538131 - 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy}-propionic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes (2009-05-26),

13. 7399777 - Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals (2008-07-15),

14. 7365084 - Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals (2008-04-29),

15. 7335671 - Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals (2008-02-26),

Title: Inventor Eugen Falk: Pioneering Innovations in Frankfurt-am-Main

Introduction: Eugen Falk is a distinguished inventor based in Frankfurt-am-Main, Germany, known for his groundbreaking contributions to various technological fields.

Latest Patents: Eugen Falk holds several patents in the areas of renewable energy, sustainable transportation, and advanced materials, showcasing his commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Eugen Falk has worked with leading research institutions and companies to develop cutting-edge technologies that have revolutionized industries worldwide.

Collaborations: Throughout his career, Eugen Falk has collaborated with top engineers, scientists, and inventors, fostering a culture of innovation and excellence in all his projects.

Conclusion: Eugen Falk's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]